Starpharma (OTCMKTS:SPHRY, ASX:SPL) looks set to soar in early deals in New York after it revealed were described as “very exciting” results from the ongoing development of a potential ovarian cancer drug.
The company’s candidate – described as an antibody-targeted DEP conjugate – in an ovarian cancer model significantly outperformed existing therapies, it said.
In the model, the DEP conjugate showed complete tumour regression and 100% survival, Starpharma told investors.
The experiments results show both improved anticancer effectiveness and survival compared to Roche’s Kadcyla and Herceptin, it added.
“We are very excited by these latest results for our targeted DEP™ conjugates and feedback from commercial parties on this new data has been very positive indeed,” it said in a statement.
The company added that talks are currently underway with a number of pharmaceutical companies regarding its targeted DEP conjugate and its technology platform.
In Sydney, where the company is also listed, the shares gained 1.74 Australia cents or 24% to trade at 90 cents each.